Laroche Daniel, Adebayo Ayobami, Ng Chester
Department of Ophthalmology, Icahn School of Medicine at Mount Sinai and New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA.
Advanced Eyecare of New York, New York, NY, USA.
Clin Ophthalmol. 2024 Oct 9;18:2843-2849. doi: 10.2147/OPTH.S481823. eCollection 2024.
The Hydrus Microstent has been shown to be efficacious in the treatment of Open-angle Glaucoma. We previously reported 1-year results of the Hydrus Microstent in Black and Afro-Latino patients.
Here we report two-year results of the Hydrus Microstent in Black and Afro-Latino patients with mild to moderate open-angle glaucoma.
This was a retrospective, nonrandomized study that was carried out at two private practices in Harlem, NY and Queens, NY.
This study consisted of Black and Afro Latino patients who had a Hydrus Microstent implanted for the treatment of glaucoma. The evaluated parameters were intraocular pressure (IOP), reductions in the number of medications, mean deviation on visual field test and visual acuity. We excluded persons with advanced glaucoma and incomplete data. We included those with mild to moderate glaucoma and had complete two-year follow-up data.
The study consisted of 86 patients and 86 eyes. The mean age was 69. The mean pre-op IOP was 14.1 on 2.17 medications. At two years the mean IOP was 14 (p = 0.651) on 0.42 medications (p = 0.000003); 88% of patients were medication free (p = 0.651), The MD on the visual field changed little from -5.73 preoperatively to -5.21 at two years. There were 3 intraocular pressure spikes and 1 case of hyphema that were treated and had complete resolution. No patients required secondary surgery.
Our results show that at two years the Hydrus Microstent can maintain low intraocular pressures, reduce medication burden and, in aggregate, experienced little change in visual field Mean Deviation in Black and Afro Latino patients with mild to moderate glaucoma.
Hydrus微支架已被证明在开角型青光眼的治疗中有效。我们之前报告了Hydrus微支架在黑人和非裔拉丁裔患者中的1年研究结果。
在此,我们报告Hydrus微支架在患有轻至中度开角型青光眼的黑人和非裔拉丁裔患者中的2年研究结果。
这是一项回顾性、非随机研究,在纽约哈莱姆区和皇后区的两家私人诊所进行。
本研究纳入了因治疗青光眼而植入Hydrus微支架的黑人和非裔拉丁裔患者。评估参数包括眼压(IOP)、药物使用数量的减少、视野测试中的平均偏差和视力。我们排除了患有晚期青光眼和数据不完整的患者。我们纳入了患有轻至中度青光眼且有完整两年随访数据的患者。
该研究包括86名患者和86只眼睛。平均年龄为69岁。术前平均眼压为14.1,使用2.17种药物。两年时,平均眼压为14(p = 0.651),使用0.42种药物(p = 0.000003);88%的患者无需使用药物(p = 0.651),视野的平均偏差从术前的-5.73变化不大,两年时为-5.21。有3次眼压峰值和1例前房积血,经过治疗后完全消退。没有患者需要二次手术。
我们的结果表明,在两年时,Hydrus微支架可以维持低眼压,减轻药物负担,总体而言,在患有轻至中度青光眼的黑人和非裔拉丁裔患者中,视野平均偏差变化不大。